Last reviewed · How we verify
glargine basal insulin and glulisine prandial insulin — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
glargine basal insulin and glulisine prandial insulin (glargine basal insulin and glulisine prandial insulin) — Emory University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| glargine basal insulin and glulisine prandial insulin TARGET | glargine basal insulin and glulisine prandial insulin | Emory University | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- glargine basal insulin and glulisine prandial insulin CI watch — RSS
- glargine basal insulin and glulisine prandial insulin CI watch — Atom
- glargine basal insulin and glulisine prandial insulin CI watch — JSON
- glargine basal insulin and glulisine prandial insulin alone — RSS
Cite this brief
Drug Landscape (2026). glargine basal insulin and glulisine prandial insulin — Competitive Intelligence Brief. https://druglandscape.com/ci/glargine-basal-insulin-and-glulisine-prandial-insulin. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab